<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04096027</url>
  </required_header>
  <id_info>
    <org_study_id>19-FCLV-101</org_study_id>
    <nct_id>NCT04096027</nct_id>
  </id_info>
  <brief_title>Cabergoline Before or After Oocyte Collection for Follicular Resolution</brief_title>
  <official_title>Cabergoline Before or After Oocyte Collection for Follicular Resolution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fertility Center of Las Vegas</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fertility Center of Las Vegas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized trial comparing the efficacy of two different times of administration of
      cabergoline in patients undergoing controlled ovarian stimulation and oocyte collection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Laboratory personnel will not be informed of the subject's group assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Discomfort level</measure>
    <time_frame>5 days after egg collection</time_frame>
    <description>Self-assessed discomfort level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mature oocyte rate per follicular puncture</measure>
    <time_frame>Within 24 hours of egg collection</time_frame>
    <description>Ratio of mature oocytes obtained to punctured ovarian follicles</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ovarian volume</measure>
    <time_frame>5 days post retrieval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oocyte count</measure>
    <time_frame>Within 24 hours of egg collection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oocyte to follicle ratio</measure>
    <time_frame>Within 24 hours of egg collection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>M1 oocyte rate</measure>
    <time_frame>Within 24 hours of egg collection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>M1 to M2 oocyte ratio</measure>
    <time_frame>Within 24 hours of egg collection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aneuploidy rate</measure>
    <time_frame>Within 14 days of egg collection</time_frame>
    <description>Genetic test results of embryos for patients who opt for such testing.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Early administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabergoline administered the day before egg collection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabergoline administered after egg collection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabergoline Pill</intervention_name>
    <description>0.5 mg cabergoline pill taken orally</description>
    <arm_group_label>Early administration</arm_group_label>
    <arm_group_label>Late administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult female at least 18 years of age intending to undergo ovarian stimulation for a
             cycle of IVF.

          2. Ability read and understand English sufficiently to obtain informed consent and
             complete a study diary.

          3. Pre-implantation genetic screening (PGS) is allowed.

          4. Egg donors are allowed.

          5. Patients using a gestational carrier are allowed.

          6. Patients with prior IVF cycles are allowed, but no patient can undergo more than one
             cycle with oocyte collection under this study.

        Exclusion Criteria:

          1. Egg banking, donor egg banking, or any cycle type that would preclude immediate
             culture to blastocyst stage.

          2. Patients that would be unavailable for the follow-up ultrasound 5 days post-retrieval,
             such as patients that live far from the clinic (e.g. out of state).

          3. Uncontrolled hypertension.

          4. Ergot alkaloid hypersensitivity or allergy.

          5. History of pulmonary, pericardial, retroperitoneal fibrotic disorders.

          6. History of bipolar disorder, schizophrenia, or psychotic illness.

          7. Breast feeding.

          8. History of eclampsia or pre-eclampsia.

          9. Severe hepatic dysfunction.

         10. Current use of any dopamine receptor agonist or antagonist for any purpose, including,
             but not limited to, cabergoline (Dostinex), aripiprazole (Abilify), bromocriptine
             (Parlodel), methylphenidate (Ritalin), buproprion (Wellbutrin, Zyban),
             lisdexamfetamine (Vyvanse).

         11. Any condition that, in the opinion of the physician or principal investigator, would
             place the patient at undue risk under this protocol or would otherwise make the
             protocol inappropriate for that subject.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Shapiro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fertility Center of Las Vehas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruce Shapiro, MD</last_name>
    <phone>7022541777</phone>
    <email>drshapiro@fertilitycenterlv.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fertility Center of Las vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arlyn Garcia</last_name>
      <phone>702-254-1777</phone>
      <email>arlyn@fertilitycenterlv.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 16, 2019</study_first_submitted>
  <study_first_submitted_qc>September 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cabergoline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

